Key result
Serum exo-miR-92b-5p discriminates HFrEF patients from healthy controls with ~83% specificity.
Why the study?
Does serum exo-miR-92b-5p serve as a diagnostic biomarker for HFrEF in patients hospitalized for acute heart failure?
Population
Patients with heart failure with reduced ejection fraction admitted to the hospital for acute heart failure…
Comparison
Measurement of serum exosomal miRNAs vs Healthy volunteers (control group)
Design
Case-control
Authors
Loading...
Serum exo-miRNAs may aid acute HFrEF diagnosis; leaves open clinical utility pending larger prospective validation.
Case-Control
Does serum exo-miR-92b-5p serve as a diagnostic biomarker for HFrEF in patients hospitalized for acute heart failure?
Effect estimate: Sensitivity 71.4%, Specificity 83.3%
p-value: p=<0.001
Serum exosomal miR-92b-5p is elevated in HFrEF patients and correlates with echocardiographic parameters, suggesting its potential as a diagnostic biomarker.
Wu et al. (2018) conducted a case-control in Heart failure with reduced ejection fraction (HFrEF). Serum exo-miR-92b-5p vs. Healthy volunteers was evaluated on Discrimination between HFrEF patients and controls (Sensitivity 71.4%, Specificity 83.3%, p=<0.001). Serum exo-miR-92b-5p levels significantly discriminated HFrEF patients from healthy controls with a sensitivity of 71.4% and specificity of 83.3% (P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: